ArticleProceedings of the National Academy of Sciences of the United States of America2026
A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice.
Zhe Yuan, Nathan L Board, Miaoyun Zhao, Guorui Zu, Srona Sengupta, Qingsheng Li, Janet D Siliciano, Robert F Siliciano, Luis J Montaner
Abstract read
In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Zhe Yuan *The Wistar Institute, Philadelphia, PA 19104.
Nathan L Board *Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-5208-9970 Miaoyun ZhaoThe Wistar Institute, Philadelphia, PA 19104.
Guorui ZuThe Wistar Institute, Philadelphia, PA 19104.
Srona SenguptaDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Qingsheng LiThe Wistar Institute, Philadelphia, PA 19104.
Janet D SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Robert F SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-1764-1993 Funding
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MIndividualized HIV Curative Combination Strategy against Persistent HIV on ARTUM1AI191272 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, ROBERT F SILICIANO · 2025 to 2026
$6.9MHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P30AI045008HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164556HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164560HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI191272NIAID NIH HHS UM1 AI164570
6 · The paper itselfAbstract
Bispecific antibodies that reroute cytotoxic effectors toward infected cells are promising HIV-1 cure agents, yet existing formats bind Env and are limited by antigenic variation and Env down-regulation. We engineered a TCR-mimic single-chain diabody, HI12, that recognizes a conserved Pol-derived peptide presented by HLA-A*02:01 and evaluated its effect in HLA-matched, HIV-infected humanized mice. When administered during early antiretroviral therapy (ART), HI12 was well tolerated, activated CD8
Indexed as
Antibodies, BispecificHIV-1HIV InfectionsProvirusesReceptors, Antigen, T-CellAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansMiceAntibodies, BispecificReceptors, Antigen, T-Cellbispecific antibodiesHIVhumanized miceTCR-mimic
Identifiers
PMID42546194
PMCPMC13462821
What OpenQuestion holds
Textmetadata
Read underepoch 390